Micieli G, Tassorelli C, Iannacchero R, Lodola E, Barbieri P, Nappi G
Department of Neurology, C. Mondino Foundation, University of Pavia, Italy.
Arzneimittelforschung. 1990 Feb;40(2 Pt 1):150-6.
The aim of the study was to evaluate in man the dose-effect relationship of ibopamine solution 0.25%, 0.50% and 1% on the pupillary diameter and the pupillary reflex to light stimulus and near vision. A cross-over study was performed in comparison with a placebo and with tropicamide solution 1% in 18 healthy volunteers. The results show that ibopamine 1% determines a marked mydriatic effect. At the doses used, it produces a maximum increase of the pupillary diameter with a dose-effect relationship which does not depart significantly from a straight line. The maximum mydriatic effect of ibopamine 1% is significantly greater than that of tropicamide 1%. The mydriatic effect of ibopamine lasts for about 3 h; that of tropicamide lasts longer. Tropicamide 1% markedly and for a long period inhibits the pupillary reflex both to light and to near vision. The effect of ibopamine 1% on the pupillary reflex to near vision is slight, while on the reflex to light stimulus it is essentially comparable to that of tropicamide.
该研究旨在评估0.25%、0.50%和1%的异波帕明溶液对人体瞳孔直径以及瞳孔对光刺激和近视力反射的剂量效应关系。在18名健康志愿者中进行了一项交叉研究，与安慰剂和1%的托吡卡胺溶液进行比较。结果表明，1%的异波帕明具有显著的散瞳作用。在所使用的剂量下，它使瞳孔直径最大程度增加，剂量效应关系与直线无显著偏差。1%异波帕明的最大散瞳作用明显大于1%托吡卡胺的散瞳作用。异波帕明的散瞳作用持续约3小时；托吡卡胺的散瞳作用持续时间更长。1%托吡卡胺显著且长期抑制瞳孔对光和近视力的反射。1%异波帕明对瞳孔近视力反射的作用轻微，而对光刺激反射的作用与托吡卡胺基本相当。
Zotero 插件